---
title: "Summit Therapeutics (SMMT) Receives a Rating Update from a Top Analyst"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284973425.md"
description: "Summit Therapeutics (SMMT) received a Hold rating from analyst Faisal Khurshid of Jefferies, with a price target of $17.00, while shares closed at $16.12. Khurshid has a 69.1% average return and 62.77% success rate. The analyst consensus for Summit is Strong Buy, with a price target of $31.42, indicating a 94.97% upside. Piper Sandler also maintained a Hold rating with a $16.00 price target."
datetime: "2026-05-02T17:05:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284973425.md)
  - [en](https://longbridge.com/en/news/284973425.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284973425.md)
---

# Summit Therapeutics (SMMT) Receives a Rating Update from a Top Analyst

In a report released yesterday, Faisal Khurshid from Jefferies maintained a Hold rating on Summit Therapeutics, with a price target of $17.00. The company’s shares closed yesterday at $16.12.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Khurshid covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Syndax Pharmaceuticals, and Revolution Medicines. According to TipRanks, Khurshid has an average return of 69.1% and a 62.77% success rate on recommended stocks.

Summit Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $31.42, which is a 94.97% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Hold rating on the stock with a $16.00 price target.

### Related Stocks

- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [SNDX.US](https://longbridge.com/en/quote/SNDX.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22](https://longbridge.com/en/news/286816644.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md)